Lexaria Bioscience (LEXX) Cash from Investing Activities (2010 - 2026)
Lexaria Bioscience (LEXX) posted Cash from Investing Activities of -$27089.0 for Q2 2026, up 49.75% sequentially from -$53909.0 in Q1 2026, and down 39.33% YoY from -$44646.2 in Q2 2025.
Lexaria Bioscience (LEXX) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Lexaria Bioscience has reported Cash from Investing Activities for 17 years, with the latest figure at -$27089.0 in Q2 2026.
- Quarterly Cash from Investing Activities fell 39.33% year-over-year to -$27089.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was -$243975.0 (down 57.68% YoY) and the FY2025 annual result came in at -$243019.0, down 28.85% from the prior year.
- Cash from Investing Activities advanced to -$27089.0 in Q2 2026 per LEXX's latest filing, from -$53909.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at -$5099.0 in Q4 2025 and troughed at -$157878.0 in Q3 2025.
- A 5-year average of -$44986.4 and a median of -$36323.0 in 2022 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities plunged 2502150.0% in 2022, then surged 86.51% in 2025.
- Over 5 years, Cash from Investing Activities stood at -$34842.0 in 2022, then dropped by 14.88% to -$40026.0 in 2023, then gained by 5.55% to -$37804.0 in 2024, then soared by 86.51% to -$5099.0 in 2025, then sank by 431.26% to -$27089.0 in 2026.
- According to Business Quant data, Cash from Investing Activities over the past three periods registered -$27089.0, -$53909.0, and -$5099.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -45.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -92.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 329.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | -49.35 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -363.46 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -3.17 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 24.51 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -229.72 Mn |
| 10 | Lexaria Bioscience | 10.15 Mn | 6.54 Mn | - | -27,089.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | -27,089.00 |
| May 31, 2026 | -27,089.00 |
| Feb 28, 2026 | -53,909.00 |
| Feb 28, 2026 | -53,909.00 |
| Nov 30, 2025 | -5,099.00 |
| Nov 30, 2025 | -5,099.00 |
| Aug 31, 2025 | -157,878.00 |
| Aug 31, 2025 | -157,878.00 |
| May 31, 2025 | -19,443.00 |
| May 31, 2025 | -19,443.00 |
| Feb 28, 2025 | -27,894.00 |
| Feb 28, 2025 | -27,894.00 |
| Nov 30, 2024 | -37,804.00 |
| Nov 30, 2024 | -37,804.00 |
| Aug 31, 2024 | -69,587.00 |
| Aug 31, 2024 | -69,587.00 |
| May 31, 2024 | -22,002.00 |
| May 31, 2024 | -22,002.00 |
| Feb 29, 2024 | -56,990.00 |
| Feb 29, 2024 | -56,990.00 |